| NAME | ORIGINATOR | INDICATION | DEVELOPMENT STATUS |
| ISTURISA® | Novartis | Endogenous Cushing's syndrome/ Cushing's diseases |
Approved in Europa Approved in the USA |
| CYSTADROPS® | Recordati | Corneal cysteine crystal deposits in patients with cystinosis | Filed in the USA Development of new formulations in EU and in USA |
| REAGILA® | Gedeon Richter | Schizophrenia | Pediatric post-approval development plan |
| metadone | Treatment of cancer-related pain in cases of resistance or intolerance to other opioids | Approved in France | |
| CARBAGLU® | Orphan Europe (Recordati) | Hyperammonaemia due to NAGS deficiency and to the main organic acidemias | Development of new formulations in EU and USA Filed in the USA for the organic acidemias indication |
| REC 0438 | Recordati/UFPeptides | New indications | Preclinical development |
| REC 0559 | Recordati/Mime Tech | Neurotrophic keratitis | Formulation development Clinical development planning |
| REC 0545 | Recordati/AP-HP | Acute decompensation episodes in MSUD | Formulation development Retrospective study in France and Germany |